Regenxbio (RGNX) announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the agreement, Regenxbio and Nippon Shinyaku will develop and commercialize RGX-121 for Mucopolysaccharidosis II, also known as Hunter syndrome and RGX-111 for Mucopolysaccharidosis I, also known as Hurler syndrome in the United States and Asia. RGX-121 is on track to be the first gene therapy for MPS II, with potential FDA approval as early as late 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- IBM initiated, Southwest upgraded: Wall Street’s top analyst calls
- Regenxbio downgraded to Neutral from Buy at Goldman Sachs
- Regenxbio resumed with an Outperform at Raymond James
- Biotech Alert: Searches spiking for these stocks today
- Morning Movers: H&E skyrockets following deal to be acquired by United Rentals